Skip to main content
search

Late Clinical

Sign up

Latest resources

Featured resource

Upcoming late clinical webinars

Latest late clinical blogs

Meet our experts at the following events

Live Events

Certara Biotech Forum: Workshop on Developing Investor-Ready Strategies

May 7, 2026 – San Diego, CA
Conference

ISPOR International Annual Conference 2026

May 17 - 20, 2026 – Philadelphia, PA
Conference

CDISC EU 2026

May 18 - 22, 2026 – Milan, Italy

All late clinical resources

Mean Residence Time (MRT): Understanding How Long Drug Molecules Stay in the Body

Modeling and Simulation - PK/PD, Blog, Knowledge Base

Extending the Value of Antibody–Drug Conjugates: Model-Informed Labeling, Expansion, and Market Access

ADC, Certara Services, Clinical Pharmacology, Drug Development, Modeling and Simulation, On-Demand Webinar

How Certara Enabled Fruquintinib FDA Approval for Metastatic Colorectal Cancer

Certara Services, Clinical Pharmacology, Clinical Trials, Drug Development, Model Informed Drug Development, Modeling and Simulation, Pharmacometrics, Therapeutic Specialties, Case Study

Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations

Certara Products, Certara Products - Phoenix, Certara Products - Simcyp, Certara Services, Clinical Pharmacology, Drug Development, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Webinar

Platforms for collaboration between sponsors and CROs: 5 ways CROs can scale efficiently while maximizing validation assurance

Certara Products - Pinnacle 21, Blog

Data Fabrics in Pharma: Connecting Data for Better Decisions

Certara Products, Certara.AI, Drug Development, Blog

Pinnacle 21 Community or Enterprise: How to decide which is right for your study

Certara Products - Pinnacle 21, Clinical Trials, Data Standards, Webinar

How Bayesian Design Is Reshaping Clinical Development

Certara Services, Press Coverage, Video

Where Did the 80-125% Bioequivalence Criteria Come From?

Modeling and Simulation - PK/PD, Blog, Knowledge Base

An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors

Biologics, Cardiovascular, Certara Services, Clinical Pharmacology, Clinical Trials, Drug Development, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Publication

Right Dose, Right Regimen: Model-Informed Strategies for Antibody–Drug Conjugates (ADCs)

ADC, Biologics, Certara Services, Clinical Pharmacology, Clinical Trials, Drug Development, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Therapeutic Specialties, On-Demand Webinar

Why the Most Important Phase 3 Decisions Should Be Made Before Phase 3

Clinical Pharmacology, Clinical Trials, Drug Development, Model Informed Drug Development, Model-Based Meta-Analysis (MBMA), Modeling and Simulation, Modeling and Simulation - QSP, Blog
Sign up to newsletter

Why sign up? Because transforming drug development is not just our goal—it’s our obsession. If it’s yours too, then be the first to know of new insights and join us in pushing the boundaries of science.